Dislipemia diabética, síndrome metabólico y riesgo cardiovascular

American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2001;24:S5-20. King, 1998, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 Stern, 1997, Glycemia and cardiovascular risk, Diabetes Care, 20, 1501, 10.2337/diacare.20.10.1501 Gray, 1997, Cardiovascular disease in diabetes mellitus Paluzie, 2001, Control de factores de riesgo en pacientes coronarios: estudio EUROASPIRE, Rev Esp Cardiol, 54, 167 Stamler, 1993, Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial, Diabetes Care, 16, 434, 10.2337/diacare.16.2.434 Kannel, 1990, Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience, Am Heart J, 120, 672, 10.1016/0002-8703(90)90026-T 1998, Economic consequences of diabetes mellitus in the US in 1997, Diabetes Care, 21, 296, 10.2337/diacare.21.2.296 Hu, 2001, The impact of diabetes meliltus on mortality from all causes and coronary heart disease in women: ten years of followup, Arch Intern Med, 161, 1717, 10.1001/archinte.161.14.1717 Haffner, 1998, Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N Engl J Med, 339, 229, 10.1056/NEJM199807233390404 Evans, 2002, Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies, BMJ, 324, 939, 10.1136/bmj.324.7343.939 Lee, 2004, Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction, Circulation, 109, 855, 10.1161/01.CIR.0000116389.61864.DE Cullen, 1999, High risk strategies for atherosclerosis, Clin Chim Acta, 286, 31, 10.1016/S0009-8981(99)00092-3 2002, Management of dyslipemia in adults with diabetes (Position Statement), Diabetes Care, 25, 74, 10.2337/diacare.25.2007.S74 Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97. 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. Caixas, 1997, Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients, Diabetes, 46, 1207, 10.2337/diabetes.46.7.1207 Lyons, 1992, Lipoprotein glycation and its metabolic consequences, Diabetes, 41, 67, 10.2337/diab.41.2.S67 Palma Gámiz, 2004, Fisiopatología del daño vascular en la diabetes mellitus tipo 2 y el síndrome metabólico, Rev Esp Cardiol Supl, 4, F6 Vinik, 2001, Platelet dysfunction in type 2 diabetes, Diabetes Care, 24, 1476, 10.2337/diacare.24.8.1476 Schneider, 1993, Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients, Diabetes, 42, 1, 10.2337/diabetes.42.1.1 Assmann, 1994, Identification of individuals at high risk for myocardial infarction, Atherosclerosis, 110, S11, 10.1016/0021-9150(94)05386-W Betteridge, 1997, LDL heterogeneity: implications for atherogenicity in insulin resistance and NIDDM, Diabetologia, 40, S149, 10.1007/s001250051434 McNamara, 1987, Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results from the Framingham Offspring Study, Arteriosclerosis, 7, 483, 10.1161/01.ATV.7.5.483 Assmann, 1996, Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men, Am J Cardiol, 77, 1179, 10.1016/S0002-9149(96)00159-2 Masana, 2002, Mecanismos de la dislipemia en la diabetes mellitus tipo 2, Clin Invest Arterioscl, 14, 24 Haffner, 1990, Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?, JAMA, 263, 2893, 10.1001/jama.1990.03440210043030 Mykkanen, 1993, Cardiovascular disease risk factors as predictors of type 2 (non-insulin dependent) diabetes mellitus in elderly subjects, Diabetologia, 36, 553, 10.1007/BF02743273 Hu, 2002, Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes, Diabetes Care, 25, 1129, 10.2337/diacare.25.7.1129 McNeill, 2005, The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study, Diabetes Care, 28, 385, 10.2337/diacare.28.2.385 Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Ridker, 2004, Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?, Circulation, 109, 2818, 10.1161/01.CIR.0000132467.45278.59 Festa, 2000, Chronic subclinical inflammation as part of the insulin resistance sindrome, Circulation, 102, 42, 10.1161/01.CIR.102.1.42 Ridker, 1997, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N Engl J Med, 336, 973, 10.1056/NEJM199704033361401 Reilly, 2003, The metabolic syndrome: more than the sum of its parts?, Circulation, 108, 1546, 10.1161/01.CIR.0000088846.10655.E0 Ridker, 2003, C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women, Circulation, 107, 391, 10.1161/01.CIR.0000055014.62083.05 Sattar, 2003, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108, 414, 10.1161/01.CIR.0000080897.52664.94 Grundy, 2003, Inflammation, hypertension, and the metabolic syndrome, JAMA, 290, 3000, 10.1001/jama.290.22.3000 Curtis, 2005, Preventing type 2 diabetes mellitus, J Am Board Fam Pract, 18, 37, 10.3122/jabfm.18.1.37 Knowler, 2002, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N Engl J Med, 346, 393, 10.1056/NEJMoa012512 Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 Heymsfield, 2000, Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults, Arch Intern Med, 160, 1321, 10.1001/archinte.160.9.1321 1999, Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Yusuf, 2001, Ramipril and the development of diabetes, JAMA, 286, 1882, 10.1001/jama.286.15.1882 Punzi, 2004, Trinity Hypertension Research Institute. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study, Curr Hypertens Rep, 6, 106, 10.1007/s11906-004-0084-7 Lindholm, 2002, Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study, J Hypertension, 20, 1879, 10.1097/00004872-200209000-00035 Scheen, 2004, Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system, Drugs, 64, 2537, 10.2165/00003495-200464220-00004 Weber, 2004, Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial, Lancet, 363, 2049, 10.1016/S0140-6736(04)16456-8 Freeman, 2001, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation, 103, 357, 10.1161/01.CIR.103.3.357 Naleway, 2003, Glycemic effects of postmenopausal hormone therapy: the estrogen/progestin replacement study, Ann Intern Med, 139, 1, 10.7326/0003-4819-139-1-200307010-00006 González Juanatey, 2004, Rosiglitazona y reducción del riesgo cardiovascular en diabéticos. Situación actual y perspectivas de futuro, Rev Esp Cardiol Supl, 4, F83 Zinman, 2001, PPAR gamma agonists in type 2 diabetes: how far have we come in «preventing the inevitable»? A review of the metabolic effects of rosiglitazone, Diabetes Obes Metab, 3, S34, 10.1046/j.1463-1326.2001.00033.x Cheng-Lai, 2000, Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes, Heart Dis, 2, 326 St John Sutton, 2002, A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes, Diabetes Care, 25, 2058, 10.2337/diacare.25.11.2058 Haffner, 2002, Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus, Circulation, 106, 679, 10.1161/01.CIR.0000025403.20953.23 Buchanan, 2002, Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women, Diabetes, 51, 2769, 10.2337/diabetes.51.9.2796